6 results
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
To test within an anxiety and aggression patient sample the effect of a tDCS intervention on (i) task-specific inhibitory control, and (ii) threat and implicit inhibitory control, attention bias and anxiety and aggression symptom reduction in a…
The primary objective of the phase II is to determine the progression free survival (PFS) at 1 year according to the RECIST 1.1 of the combination of pazopanib with weekly paclitaxel and carboplatin in platinum-resistant ovarian, fallopian tube or…
Primary objectivesThe primary objective is to assess the progression-free survival (PFS) of patients who receive bi-monthly rotations of Pazopanib and Everolimus versus patients who receive Pazopanib as a first line treatment. Secondary…
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
The study objective is to test the effect of a tDCS intervention in a sample of healthy military personnel. We investigate the effects of the intervention primarily on the intensity of fear reactions, and secondarily on cognitive performance and…